Compare CPHC & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | ASRT |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 76.0M |
| IPO Year | 2016 | 2004 |
| Metric | CPHC | ASRT |
|---|---|---|
| Price | $15.85 | $18.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 766.0 | ★ 268.7K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $59,227,000.00 | ★ $118,713,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.14 | N/A |
| 52 Week Low | $14.49 | $0.58 |
| 52 Week High | $21.61 | $20.45 |
| Indicator | CPHC | ASRT |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 62.65 |
| Support Level | $14.97 | $0.70 |
| Resistance Level | $15.95 | $20.45 |
| Average True Range (ATR) | 0.10 | 0.28 |
| MACD | 0.04 | -0.29 |
| Stochastic Oscillator | 100.00 | 0.56 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.